Healthy
Conditions
Brief summary
The purpose of this study is to determine whether defined and limited changes in in vitro dissolution impact the in vivo pharmacokinetics (PK) and relative bioavailability of allopurinol and the active metabolite oxypurinol.
Detailed description
In this study, a single oral dose of Zyloprim® (300 mg tablet) and 3 separate single oral doses of 300 mg allopurinol test formulations (Regimens B, C and D) will be administered sequentially to each subject on separate occasions. Following the administration of Regimens B and C, there will be a period of interim analysis during which the PK data will be reviewed to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period.
Interventions
DRUGZyloprim® 300 mg
DRUGAllopurinol 300 mg; undergranulated, high hardness condition
There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
DRUGAllopurinol 300 mg; alternative condition 2
There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
DRUGAllopurinol 300 mg; alternative condition 3
Sponsors
Quotient Clinical
Ardea Biosciences, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Body mass index of 18.0 to 35.0 kg/m2 inclusive, or if outside the range, considered not clinically significant by the Investigator. Must not exceed 40.0 kg/m2. * Must agree to use an adequate method of contraception
Exclusion criteria
* Subjects who test positive for the HLA-B\*5801 allele. * Subjects who have received the last dose of an IMP (or treatment with a medical device) within the previous 3 months prior to Day 1 or is currently participating in another study of an IMP (or medical device). * History of any drug or alcohol abuse in the past 2 years. * Regular alcohol consumption in males \>21 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine). * Current smokers and those who have smoked within the last 12 months prior to Screening. A breath carbon monoxide reading of greater than 10 ppm at Screening. * Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at Screening. * Clinically significant screening laboratory parameters (biochemistry \[AST or ALT \> 1.5 × ULN\], hematology or urinalysis) as judged by the Investigator (laboratory parameters are listed in Appendix 1). * Positive drugs of abuse test result during Screening or at Admission (drugs of abuse tests are listed in Appendix 1). * Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results. * Subjects with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption. * History of cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease as judged by the Investigator. * Evidence of renal impairment at Screening, as indicated by an estimated creatinine clearance of \<90 mL/min using the Cockcroft-Gault equation. * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients. * Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hayfever is allowed unless it is active. * Donation or loss of greater than 400 mL of blood within the previous 3 months prior to Screening. * Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (See Section 11.4).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK profile of Zyloprim® and three dissolution test formulations of allopurinol from plasma | Predose (within 30 minutes before dosing), 15, 30, and 45 minutes postdose, and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 18, 24, 36, 48, 72, and 96 hours postdose. | PK endpoints in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUClast), area under the concentration-time curve (AUC∞) and apparent terminal half-life (t1/2) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse Events | 11 weeks | Changes in Laboratory, Electrocardiogram and Vital Signs Parameters |
Countries
United Kingdom
Outcome results
None listed